IQ EQ FUND MANAGEMENT IRELAND Ltd Has $61,000 Stock Position in Accolade, Inc. (NASDAQ:ACCD)

IQ EQ FUND MANAGEMENT IRELAND Ltd increased its position in shares of Accolade, Inc. (NASDAQ:ACCD) by 49.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 17,804 shares of the company’s stock after buying an additional 5,929 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Accolade were worth $61,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Clearline Capital LP grew its stake in shares of Accolade by 85.3% during the 3rd quarter. Clearline Capital LP now owns 1,539,578 shares of the company’s stock worth $5,927,000 after acquiring an additional 708,794 shares in the last quarter. Fairman Group LLC boosted its holdings in Accolade by 58.5% during the fourth quarter. Fairman Group LLC now owns 1,802,399 shares of the company’s stock worth $6,164,000 after purchasing an additional 665,112 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Accolade in the third quarter valued at $2,378,000. Tocqueville Asset Management L.P. increased its stake in Accolade by 100.0% in the 4th quarter. Tocqueville Asset Management L.P. now owns 580,000 shares of the company’s stock valued at $1,984,000 after buying an additional 290,000 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in Accolade by 84.1% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 634,470 shares of the company’s stock worth $2,170,000 after buying an additional 289,747 shares in the last quarter. Institutional investors and hedge funds own 84.99% of the company’s stock.

Accolade Stock Down 0.1 %

Shares of ACCD opened at $6.99 on Friday. The firm has a market cap of $573.13 million, a P/E ratio of -3.11 and a beta of 2.18. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.63 and a current ratio of 2.63. Accolade, Inc. has a 52 week low of $3.08 and a 52 week high of $10.45. The firm’s 50-day simple moving average is $6.94 and its 200 day simple moving average is $4.95.

Accolade (NASDAQ:ACCD) last posted its earnings results on Friday, January 10th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.01. Accolade had a negative return on equity of 20.74% and a negative net margin of 40.36%. On average, analysts forecast that Accolade, Inc. will post -1.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

ACCD has been the subject of several analyst reports. Morgan Stanley decreased their price objective on Accolade from $6.00 to $5.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Piper Sandler downgraded Accolade from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Stifel Nicolaus reiterated a “hold” rating and set a $7.03 price objective (down previously from $8.00) on shares of Accolade in a research note on Thursday, January 9th. William Blair downgraded Accolade from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 8th. Finally, Leerink Partners restated a “market perform” rating on shares of Accolade in a report on Wednesday, January 8th. Thirteen analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $6.51.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.